CardioVia

CardioVia is an Israeli medical device manufacturer specializing in minimally invasive cardiac access technologies. The company's flagship product, ViaOne™, is an FDA-cleared epicardial access system that enables safe, precise entry into the heart's pericardial space using a proprietary blunt-tip concealed needle design, eliminating the risk of cardiac perforation associated with traditional sharp-needle approaches. ViaOne™ incorporates a bio-impedance pressure sensor for real-time placement confirmation and a tissue-gripping mechanism that separates tissue without cutting. The platform supports multiple cardiac interventions including arrhythmia ablation, epicardial lead implantation, left atrial appendage closure (LAAC), and emerging regenerative therapies (stem cell, gene therapy, targeted drug delivery). The device has achieved FDA Breakthrough Device Designation, 510(k) clearance, and publication of feasibility and preclinical validation studies in peer-reviewed journals (JACC: Clinical Electrophysiology, Journal of Interventional Cardiac Electrophysiology). CardioVia is backed by Terumo Corporation and is launching commercialization across U.S. cardiac centers.